
~~AMENDED~~ CLAIMS

1. Use of a~~A~~ thienopyridone derivative selected from the group consisting of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-5-(4-fluorophenyl)-4-hydroxy-3-indan-5-yl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-4-hydroxy-3-indan-5-yl-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, and pharmaceutically acceptable salts and/or solvates thereof, in the preparation of a medicament for ~~use in~~ the treatment of adrenoleukodystrophy and/or adrenomyeloneuropathy.

2. The use according to claim 1, wherein said thienopyridone derivative is 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one or a pharmaceutically salt and/or solvate thereof.

~~2~~3. The ~~thienopyridone derivative selected from the group consisting of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-5-(4-fluorophenyl)-4-hydroxy-3-indan-5-yl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-4-hydroxy-3-indan-5-yl-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, and pharmaceutically acceptable salts and/or solvates thereof, for~~ use according to claim 1, wherein said thienopyridone derivative is a monohydrate potassium salt of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one having Formula (Ia):



(Ia)

~~3~~4. The ~~thienopyridone derivative selected from the group consisting of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-5-(4-fluorophenyl)-4-hydroxy-3-indan-5-yl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-4-hydroxy-3-indan-5-yl-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, and pharmaceutically acceptable salts and/or solvates thereof, for~~ use according to any one of claim~~s 1 or 2~~1 to 3, wherein said thienopyridone derivative is to be administered once or twice a day at a daily dose of 0.5mg to 3000 mg ~~for~~ to a human patient.

5. The use according to any one of claims 1 to 4, wherein said thirnopyridone derivative is to be administered once or twice a day at a daily dose of~~, preferably from~~ 20 mg to 1000 mg to a human patient.

6. The use according to any one of claims 1 to 4, wherein said thirnopyridone derivative is to be administered once or twice a day at a daily dose of~~, more preferably from~~ 60 mg to 500 mg to a human patient.

~~4~~7. The ~~thienopyridone derivative selected from the group consisting of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-5-(4-fluorophenyl)-4-hydroxy-3-indan-5-yl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-4-hydroxy-3-indan-5-yl-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, and pharmaceutically acceptable salts and/or solvates thereof, for~~ use according to any one claims 1 to ~~3~~6, wherein said thienopypridone derivative is effective to treat central demyelination, adrenocortical insufficiency or adrenal gland dysfunction.

~~5~~8. The ~~thienopyridone derivative selected from the group consisting of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-5-(4-fluorophenyl)-4-hydroxy-3-indan-5-yl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-4-hydroxy-3-indan-5-yl-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, and pharmaceutically acceptable salts and/or solvates thereof, for~~ use according to any one of claims 1 to ~~4~~7, which is for ~~use in~~ the treatment of adrenomyeloneuropathy in an adult subject.

9. The use according to claim 8, which is for use in the treatment of adrenomyeloneuropathy in a 20-39 years old adult subject.

~~6~~10. The ~~thienopyridone derivative selected from the group consisting of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-5-(4-fluorophenyl)-4-hydroxy-3-indan-5-yl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-4-hydroxy-3-indan-5-yl-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, and pharmaceutically acceptable salts and/or solvates thereof, for~~ use according to any one of claims 1 to ~~4~~7 which is for ~~use in~~ the treatment of adrenoleukodystrophy in a subject of 2 to 10 years old.

~~7~~11. The ~~thienopyridone derivative selected from the group consisting of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-5-(4-fluorophenyl)-4-hydroxy-3-indan-5-yl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-4-hydroxy-3-indan-5-yl-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, and pharmaceutically acceptable salts and/or solvates thereof, for~~ use according to any one of claims 1 to ~~6~~10, wherein the medicament ~~which~~ is to be administered by oral route.

~~8~~12. Use of ~~A~~a pharmaceutical composition comprising (i) a thienopyridone derivative selected from the group consisting of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-5-(4-fluorophenyl)-4-hydroxy-3-indan-5-yl-7H-thieno[2,3-b]pyridin-6-one, 2-chloro-4-hydroxy-3-indan-5-yl-5-phenyl-7H-thieno[2,3-b]pyridin-6-one, or a pharmaceutically acceptable salt and/or solva~~n~~te thereof and (ii) a pharmaceutically acceptable excipient in the preparation of a medicament for ~~use in~~ the treatment of adrenoleukodystrophy and/or adrenomyeloneuropathy.

13. The use of a pharmaceutical composition according to claim 12, wherein the thienopyridone derivative is 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridine-6-one and/or a pharmaceutical salt or solvate thereof.

14. The use of a pharmaceutical composition according to claim 12 or 13, herein said thienopyridone derivative is a monohydrate potassium salt of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one.